

## **HLA-DRB1** Blocking Peptide (Center)

Synthetic peptide Catalog # BP20819c

# **Specification**

## **HLA-DRB1** Blocking Peptide (Center) - Product Information

Primary Accession <u>P01911</u>

Other Accession <u>P13762</u>, <u>Q29974</u>, <u>Q30167</u>

# **HLA-DRB1** Blocking Peptide (Center) - Additional Information

## **Gene ID 3123**

#### **Other Names**

HLA class II histocompatibility antigen, DRB1-15 beta chain, DW22/DR22, MHC class II antigen DRB1\*15, HLA-DRB1, HLA-DRB2

## Target/Specificity

The synthetic peptide sequence is selected from aa 122-134 of HUMAN HLA-DRB1

## **Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

### **Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

## **Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

# **HLA-DRB1 Blocking Peptide (Center) - Protein Information**

# Name HLA-DRB1 (HGNC:4948)

### **Function**

A beta chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule. In complex with the alpha chain HLA- DRA, displays antigenic peptides on professional antigen presenting cells (APCs) for recognition by alpha-beta T cell receptor (TCR) on HLA-DRB1-restricted CD4-positive T cells. This guides antigen-specific T-helper effector functions, both antibody-mediated immune response and macrophage activation, to ultimately eliminate the infectious agents and transformed cells (PubMed:<a

 $\label{lem:http://www.uniprot.org/citations/29884618"} target="\_blank">29884618</a>, PubMed:<a href="http://www.uniprot.org/citations/22327072" target="\_blank">22327072</a>, PubMed:<a href="http://www.uniprot.org/citations/27591323" target="\_blank">27591323</a>, PubMed:<a href="http://www.uniprot.org/citations/8642306" target="_blank">8642306</a>, PubMed:<a href="http://www.uniprot.org/citations/15265931" target="_blank">15265931</a>, PubMed:<a href="http://www.uniprot.org/citations/31495665" target="_blank">31495665</a>, PubMed:<a href="http://www.uniprot.org/citations/16148104" target="_blank">16148104</a>). Typically$ 



presents extracellular peptide antigens of 10 to 30 amino acids that arise from proteolysis of endocytosed antigens in lysosomes (PubMed:<a href="http://www.uniprot.org/citations/8145819" target="\_blank">8145819</a>). In the tumor microenvironment, presents antigenic peptides that are primarily generated in tumor- resident APCs likely via phagocytosis of apoptotic tumor cells or macropinocytosis of secreted tumor proteins (PubMed:<a

href="http://www.uniprot.org/citations/31495665" target="\_blank">31495665</a>). Presents peptides derived from intracellular proteins that are trapped in autolysosomes after macroautophagy, a mechanism especially relevant for T cell selection in the thymus and central immune tolerance (PubMed:<a href="http://www.uniprot.org/citations/17182262" target="\_blank">17182262</a>, PubMed:<a href="http://www.uniprot.org/citations/23783831" target="\_blank">23783831</a>). The selection of the immunodominant epitopes follows two processing modes: 'bind first, cut/trim later' for pathogen-derived antigenic peptides and 'cut first, bind later' for autoantigens/self-peptides (PubMed:<a

href="http://www.uniprot.org/citations/25413013" target="\_blank">25413013</a>). The anchor residue at position 1 of the peptide N-terminus, usually a large hydrophobic residue, is essential for high affinity interaction with MHCII molecules (PubMed:<a

href="http://www.uniprot.org/citations/8145819" target="\_blank">8145819</a>).

#### **Cellular Location**

Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass type I membrane protein. Lysosome membrane; Single-pass type I membrane protein. Late endosome membrane; Single-pass type I membrane protein. Autolysosome membrane Note=The MHC class II complex transits through a number of intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation (PubMed:18305173). Component of immunological synapses at the interface between T cell and APC (PubMed:29884618).

#### **Tissue Location**

Expressed in professional APCs: monocyte/macrophages, dendritic cells and B cells (at protein level) (PubMed:31495665, PubMed:23783831, PubMed:19830726). Expressed in thymic epithelial cells (at protein level) (PubMed:23783831)

# **HLA-DRB1 Blocking Peptide (Center) - Protocols**

Provided below are standard protocols that you may find useful for product applications.

## Blocking Peptides

**HLA-DRB1 Blocking Peptide (Center) - Images** 

# **HLA-DRB1** Blocking Peptide (Center) - Background

Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain)







associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.

# **HLA-DRB1** Blocking Peptide (Center) - References

Lock C.B., et al. Immunogenetics 27:449-455(1988). Raymond C.K., et al. Genome Res. 15:1250-1257(2005). Balas A., et al. Hum. Immunol. 67:1008-1016(2006). Mungall A.J., et al. Nature 425:805-811(2003). Wu S.K., et al.J. Immunol. 138:2953-2959(1987).